ArticleJournal of orthopaedic surgery and research2025
TRIM3 exacerbates chondrocyte apoptosis through suppression of AKT/mTOR signaling pathway in osteoarthritis.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionAs a leading cause of disability worldwide, osteoarthritis (OA) progressively degrades articular cartilage. The incomplete understanding of OA's molecular mechanisms hinders development of disease-modifying treatments.
methodsWe analyzed GEO database knee OA datasets to track TRIM3 expression dynamics throughout disease progression. Western blot and IHC quantified TRIM3 protein differences between OA and normal cartilage. TRIM3-knockdown chondrocytes showed altered Bcl-2/Bax ratios via qRT-PCR/Western blot, with p-AKT/p-mTOR levels indicating AKT/mTOR activation. To establish functional dependency, siTRIM3 cells were treated with mTOR inhibitor followed by reevaluation of Bcl-2/Bax balance. Apoptotic responses to IL-1β stimulation were quantified by flow cytometry, while collagen II (COL2A1) preservation was visualized via immunofluorescence.
resultsIntegrated bioinformatics and IHC analyses demonstrated significant TRIM3 upregulation in OA cartilage compared to healthy controls (P = 0.043). TRIM3 depletion exerted dual protective effects: (1) modulating apoptotic regulators by decreasing Bax while increasing Bcl-2 expression, and (2) enhancing AKT/mTOR pathway activation evidenced by elevated p-AKT/p-mTOR levels.Notably, mTOR inhibition abolished these effects, restoring pro-apoptotic Bax expression and suppressing anti-apoptotic Bcl-2 (p < 0.01), confirming pathway mediation. Functionally, siTRIM3 conferred 40% reduction in IL-1β-induced apoptosis (P = 0.0081) and remarkably preserved COL2A1 integrity, exhibiting 2.3-fold higher fluorescence intensity versus controls.
conclusionOur findings establish TRIM3 as a novel regulator of OA pathogenesis that exacerbates disease progression through AKT/mTOR pathway suppression, thereby promoting chondrocyte apoptosis and extracellular matrix degradation. Therapeutic targeting of TRIM3 may represent a promising strategy to attenuate cartilage degeneration in OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.